Belite Bio, Inc

NASDAQ:BLTE

Biotechnology

Healthcare
$156.23 +0.31%

+$0.46 today

Market cap
$6.29B
Beta
-1.24
P/E (TTM)
-65.9
EPS (TTM)
-$2.26
52W Low $56.10High $200.00

Volume 0.09M

Average 0.17M

BLTE Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Belite Bio, IncNASDAQ: BLTE

Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026

Selling, general & admin grows, but more slowly than its trailing trend

Q3 FY2026 selling, general & admin of $21.43M rose 68.6% year over year, behind the +131.9% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 28.4% from the prior quarter. Over 3 fiscal years it compounded at +114.2% a year.

Context

  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 5 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +286.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$21.43M+28.4% QoQ
Last fiscal yearDec 2025
$38.83M+286.1% YoY
LTMSep 2026
$68.6M+131.9% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+68.6%-100.0%-168.6 pp
1 year+286.1%-100.0%-386.1 pp
3-year CAGR+114.2%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
38.83M USD
Year-over-year change
+286.1%
4-year CAGR
+101.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How BLTE compares with its peers on the latest reported figures

  • BLTE's LTM Sep 2026 selling, general & admin of $68.6M is the highest of the 6 companies compared; the peer median is $29.24M.
  • Its year-over-year change of +131.9% is the highest of 6, against a peer median of +1.3%.
  • Over three fiscal years its annual growth of +114.2% compares with a peer median of -5.0%.
BLTE Competitors Peer median
Selling, General & Admin for BLTE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BLTEBelite Bio, IncLTM Sep 2026$68.6M +131.9%+114.2%—
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$53.04M +1.3%-5.0%696.5%
KODKodiak Sciences Inc.LTM Sep 2026$42.74M -6.8%-6.1%—
OCGNOcugen, Inc.LTM Mar 2026$29.24M +9.4%-8.0%654.9%
IRDOpus Genetics, Inc.LTM Mar 2026$21.57M +8.6%+44.6%180.0%
KLRSKalaris Therapeutics IncLTM Mar 2026$15.32M -41.8%+90.0%—
Peer median (excluding BLTE) $29.24M+1.3%-5.0%654.9%

Competitors are the stored peer set for BLTE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development7.42M8.87M24.84M29.94M45.38M
Selling, General & Admin2.38M3.95M6.82M10.06M38.83M
Operating Expenses9.8M12.82M31.67M40M84.21M
Depreciation & Amortization30K198K399K449K464K
EBITDA(9.64M)(12.43M)(31.2M)(35.67M)(77.15M)
EBITDA Margin—————
Operating Income(9.8M)(12.82M)(31.67M)(40M)(84.21M)
Operating Margin—————
Interest Income5K23K74K3.74M0
Interest Expense016K25K20K0
Other Income / Expenses131K173K45K3.86M6.6M
Income Before Tax(9.67M)(12.65M)(31.62M)(36.14M)(77.61M)
Pre-Tax Margin—————
Income Tax Expense009K6K0
Net Income(9.67M)(12.65M)(31.63M)(36.14M)(77.61M)
Net Margin—————
EPS (Basic)(0.40)(0.63)(1.19)(1.18)(2.31)
EPS (Diluted)(0.40)(0.63)(1.19)(1.18)(2.31)
Weighted Avg Shares24.1M19.98M26.59M30.54M33.54M
Weighted Avg Shares (Diluted)24.1M19.98M26.59M30.54M33.54M

Belite Bio, Inc

NASDAQ:BLTE

Intrinsic Alpha fair value

Locked

Current Price

$156.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.